Effectiveness of methotrexate versus prednisone as first-line treatment for pulmonary sarcoidosis
作者
Vivienne Kahlmann,Marcel Veltkamp,Karen Moor,Montse Janssen Bonás,Rémy L.M. Mostard,Rein Van Rijswijk,Jan van der Maten,Miranda Geelhoed,Linda Moonen,Marieke J. Overbeek,Hubertus F.J.M. Koopman,Marco Grootenboers,Esther J. Nossent,Michiel Wagenaar,Henk Kramer,Pascal L. M. L. Wielders,René E. Jonkers,Stefan Walen,Brigitte A.H.A. Bogaarts,René Kerstens
出处
期刊:The European respiratory journal [European Respiratory Society] 日期:2024-09-14卷期号:: OA948-OA948被引量:1
标识
DOI:10.1183/13993003.congress-2024.oa948
摘要
Background: The mainstay treatment for pulmonary sarcoidosis is prednisone, which often causes many side effects. There is an urgent need for better evidence-based treatments. Methotrexate appears to have fewer side effects, but has not been studied as first-line treatment. Aim: To investigate the effectiveness of methotrexate compared with prednisone as first-line treatment for pulmonary sarcoidosis. Methods: The PREDMETH study was developed by clinicians, researchers and patients. It is a randomized, multi-centre, non-inferiority trial ( NCT04314193 ). Treatment-naïve patients with pulmonary sarcoidosis were randomly assigned to receive prednisone or methotrexate (1:1) at a predefined dosing schedule for a period of 24 weeks. The primary endpoint is change in Forced Vital Capacity (FVC) at 24 weeks (protocol: PMID 33076885). The Dutch Lung Foundation funded the study. Results: We randomized 137 patients, 74.5% male and with a mean age of 46.7 years (SD 11.87). FVC at baseline was 77.36% (SD 14.36) and diffusion capacity of the lungs for carbon monoxide was 69.78% (SD 14.87). Table 1 shows the main baseline characteristics. Discussion: The PREDMETH trial is a unique study that will provide better evidence-based treatment for pulmonary sarcoidosis. If methotrexate is as effective as prednisone with fewer side effects this will initiate a change in practice. The results of the primary endpoint are expected August 2024. erj;64/suppl_68/OA948/F1 F1 F1